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Abstract
The kinetics of circulating Candida mannan and anti-mannan antibodies were studied in consecutive plasma samples, obtained upon hos-
pital admission, of 21 patients with microbiologically proven invasive candidiasis and 30 control patients who underwent myelo-ablative
chemotherapy. The detection of Candida anti-mannan antibodies preceded the diagnosis of invasive candidiasis in infected patients, and
the antibodies were detected signiﬁcantly more often in patients who had experienced multiple episodes of neutropenia than in the
control group (OR 8.9, 95% CI 5.6–14.3; p <0.05). Mannan was predominantly detected in patients who developed invasive candidiasis
during their ﬁrst episode of neutropenia (OR 3.7, 95% CI 1.4–9.7; p <0.05). This observation suggests that patients with multiple epi-
sodes of neutropenia have been previously exposed to Candida and that the presence of anti-mannan antibodies in these patients might
be associated with an increased risk of developing clinically manifest invasive candidiasis.
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Introduction
Invasive Candida infections continue to be associated with
signiﬁcant morbidity and mortality [1], despite the availability
of new potent antifungal agents such as the echinocandins
[2,3]. One of the factors that has emerged as pivotal in
improving the outcome of patients with invasive candidiasis
is the timing of initiation of antifungal therapy [4,5]; these
studies have shown that any delay reduces the chance of sur-
vival. However, this window of opportunity is lost when
treatment is initiated on the basis of positive blood cultures,
due to the relatively long time to detection for Candida
species when using commercial blood culture systems [6].
Biological markers are increasingly used for the early diagno-
sis of opportunistic fungal infections in immunocompromised
patients, and these primarily involve systems that detect cir-
culating fungal antigens [7]. The sensitivity and speciﬁcity of
these systems vary, ranging from 0% to 100% and from 88%
to 100%, respectively, due to differences in methodology and
different patient groups [8–14]. Although the systems avail-
able for diagnosing invasive Candida infection combine man-
nan and anti-mannan antibody detection, the role of antibody
detection is limited, especially in neutropenic patients. It is
generally accepted that in this patient population, antibodies
are not an early marker of invasive fungal infection and, at
best, are present after the infection and following immune
recovery [15].
The kinetics of Candida-speciﬁc mannan antigen and anti-
mannan antibodies were studied in patients with haemato-
logical malignancy and invasive Candida infection, using a
commercially available system (Platelia Candida Ag and Plat-
elia Candida Ab/Ac/Ak; BioRad, Marnes-La-Coquette, France)
in order to establish whether such systems could identify
patients who require early and reliable antifungal therapy.
Subjects, Materials and Methods
Study design
The microbiological records of patients admitted to a ter-
tiary-care hospital for intensive cytotoxic chemotherapy for
a malignancy or to undergo allogenic haematopoietic stem
cell transplantation between January 1999 and December
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2008.02654.x
2005, and who had microbiologically proven invasive candidi-
asis, were reviewed. Invasive candidiasis was deﬁned accord-
ing to at least one positive culture from blood or normally
sterile tissue samples. A second selection criterion was the
availability of one or more stored serum or plasma samples
within a 4-week period preceding the microbiological diagno-
sis. The duration of neutropenia, deﬁned as a neutrophil
count of <0.5 · 109/L, was recorded for every patient. The
mean number of days of neutropenia for a single course of
chemotherapy was 8 days (standard deviation ±6 days).
Therefore, 15 days was chosen as a cut-off to categorize
patients for further analysis as those with <15 days and
those with >15 days of neutropenia prior to microbiological
conﬁrmation of Candida infection, which corresponds to a
single course or multiple courses of chemotherapy, respec-
tively. Background reactivity of the enzyme immunoassays
(EIAs) was studied in a matched control group of patients
admitted to the same ward within the same study period as
the patients with invasive candidiasis, but without docu-
mented invasive Candida infection. Besides microbiological
data, the underlying disease, cytotoxic and antimicrobial
treatment regimens were recorded for all patients. Experi-
mentation guidelines for humans from the Radboud Univer-
sity Nijmegen Medical Centre were followed in the conduct
of this research.
Sampling and microbiology
All admitted patients were intensively monitored, and this
included the twice-weekly sample collection for blood cul-
tures from each lumen of the four-lumen central venous
catheter during episodes of neutropenia. Twice weekly,
samples from mouthwashes and faeces were obtained and
cultured for the presence of Gram-negative rods and Can-
dida spp. Oral ﬂuconazole at a dose of 200 mg/day was
pre-emptively given to patients colonized with Candida albi-
cans. Colonization was deﬁned according to two subsequent
positive cultures from mouthwashes and/or faeces without
clinical signs of infection. When a patient developed fever,
additional blood samples were drawn from the central
venous catheter and by venipuncture. Febrile patients were
empirically treated with ceftazidime. Patients with invasive
yeast infection were treated with ﬂuconazole at a dose of
400 mg/day.
Serum or plasma was systemically collected twice weekly
during the neutropenic episodes of hospitalized patients and
was stored until use at )80C. Blood cultures were
incubated for 5 days in an automated blood culture system
(Bactec; Becton Dickinson, Breda, The Netherlands). All
Candida isolates were identiﬁed to the species level using
their ability to produce a germ-tube when incubated with
fetal bovine serum and by biochemical identiﬁcation for germ-
tube-negative yeasts (Auxacolor II; Biorad Laboratories).
Laboratory studies
All available serum or plasma samples were analysed for the
presence of Candida-speciﬁc mannan and anti-mannan anti-
bodies. For the detection of mannan, the Platelia Candida Ag
assay (BioRad) was used, and for anti-mannan antibody
detection, the Platelia Candida Ab/Ac/Ak assay (BioRad) was
used. Microtitre plates of the BioRad mannan and antibody
assays are coated with monoclonal anti-mannan antibody,
EBCA-1, and C. albicans cell wall mannan, respectively. All
assays were performed according to the manufacturer’s
instructions. For the BioRad mannan EIA, a result lower than
0.25 lg/L was considered to be negative, and for the BioRad
anti-mannan antibody EIA, results lower than 5 AU/mL were
considered to be negative.
Analysis
The Mann–Whitney U-test was applied to compare means.
For comparing proportions, a per-sample analysis and a per-
patient analysis were performed. A positive patient was
deﬁned as one having at least two antigen-positive or anti-
mannan antibody-positive samples. Fisher exact tests were
used to evaluate differences in proportions, and the ORs
were calculated.
Results
The patient group with a microbiologically proven invasive
Candida infection included 21 patients (13 male, eight female)
with a mean age of 40 years (range 3–65 years). Nineteen
(90.5%) patients were treated for a haematological malig-
nancy, and two patients were treated for a non-haematologi-
cal malignancy (Table 1). Twelve of 21 patients were infected
with C. albicans. The remaining nine patients were infected
with other Candida species: Candida glabrata (three), Candida
tropicalis (two), Candida krusei (one), Candida dubliniensis
(one), Candida parapsilosis (one), and Candida lusitaniae (one).
Ten and 11 patients were neutropenic for <15 days and
>15 days, respectively. Nineteen of 21 patients were colo-
nized with the same species before their infection was
microbiologically documented; in one patient, the presence
of yeast colonization was unknown, and one was not previ-
ously colonized. In total, 242 serum samples were available
for testing, being collected from each patient from the ﬁrst
day of admission until ﬁnal discharge, which ranged from
339 days before to 253 days after invasive candidiasis was
microbiologically proven (Table 1). Mannan and anti-mannan
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antibodies were detected in plasma samples of 15 patients
before the infection was microbiologically proven. The mean
proportion of antigen-positive or antibody-positive plasma
samples per patient was 60% (range 0–100%).
The control group included 30 patients (19 male, 11
female) with a mean age of 49 years (range 26–64 years).
Underlying diseases are shown in Table 1. Five patients were
neutropenic during their hospital stay for <15 days, and the
remaining 25 patients were neutropenic for >15 days.
Twenty control patients (67%) were colonized with yeasts,
12 with C. albicans, seven with C. albicans together with other
Candida spp., and one with only non-albicans Candida spp.
Four control patients had clinical signs, and there was
microbiological evidence of a superﬁcial Candida infection.
Severe mucosal barrier injury was present in 24 patients. In
total, 390 serum samples were available for testing. The
mean number of available samples per patient was compara-
ble to the mean number of collected samples in the group
of patients with invasive candidiasis (p >0.05; Mann–Whitney
U-test). The number of antigen-positive or antibody-positive
plasma samples ranged from zero to three, except for two
patients, where nine of 11 (82%) and 20 of 34 (59%) samples
were positive for anti-mannan antibody. These consecutive
samples were collected in periods of 35 and 207 days,
respectively. Except for these two patients, no distinct
pattern was observed in the remaining patients of this group.
The mean proportion of positive samples was 20% (range
0–100%), which differed signiﬁcantly from the mean propor-
tion of positive samples in the infected group (p <0.05,
Mann–Whitney U-test). Mucosal barrier injury, prior coloni-
zation, superﬁcial Candida infections and ﬂuconazole usage
were not associated with the detection of mannan antigen
or anti-mannan antibody, according to logistic regression
analysis using the ‘Enter’ method (p >0.05).
Anti-mannan antibodies were generally detected earlier
than mannan in samples of infected patients, with median
numbers of 23 days for the anti-mannan antibodies and
1 day for mannan, before the infection was microbiologically
proven (Table 2). This pattern remained when the patients
were subdivided into those who were infected with C. albi-
cans and those who were infected with non-albicans Candida
species (data not shown). Mannan was detected signiﬁcantly
more often in samples from infected patients with <15 days
of neutropenia prior to the diagnosis of invasive candidiasis
than in those with >15 days of neutropenia (Fig. 1; Fisher
exact test, p <0.05). However, anti-mannan antibodies were
detected signiﬁcantly more often in samples collected from
infected patients with >15 days of neutropenia prior to
TABLE 1. Patient demographics
Infected
patients (n = 21)
Controls
(n = 30)
Male/female 13/8 19/11
Age, years: mean (range) 40 (3–65) 49 (26–64)
Neutropenia, <15 days/>15 days 10/11 5/25
Underlying disease
AML 5 9
ALL 6 6
Myeloma 2 –
MDS 2 4
Aplastic anaemia 2 –
CLL 1 1
NHL 1 6
CML – 2
Myeloﬁbrosis – 1
MPD – 1
Non-haematological malignancy 2 –
HSCT
VUD 14 30
Autologous HSCT 1
Non-HSCT 4
Colonization
With Candida species 19 20
With Candida albicans 12 12
Number of samples 242 390
Mean number of samples/patient (range) 12 (1–42) 13 (1–34)
TABLE 2. Results of mannan and anti-mannan antibody detection in patients with microbiologically proven invasive candidiasis
and controls
Analysis
Number of
neutropenia days Patients Controls OR (95% CI) Signiﬁcance
Antigen
Per sample (no. of positive samples/total no. of samples) <15 33/92 (36%) 6/46 (13%) 3.7 (1.4–9.7) p < 0.05
>15 8/148 (5%) 14/344 (4%) 1.3 (0.6–3.3) NS
Per patient (no. of positive patientsa/total no. of patients) <15 6/10 (60%) 2/5 (40%) 2.3 (0.3–20.1) NS
>15 2/11 (18%) 3/25 (12%) 1.6 (0.2–11.4) NS
Time interval to culture median (range)b )1 ()289 to 194) NA
Antibody
Per sample (no. of positive samples/total no. of samples) <15 16/91 (18%) 0/46 (0%) NA p < 0.05
>15 77/147 (52%) 37/338 (11%) 8.9 (5.6–14.3) p < 0.05
Per patient (no. of positive patientsa/total no. of patients) <15 4/10 (40%) 0/5 (0%) NA NS
>15 7/11 (64%) 3/25 (12%) 12.8 (2.3–71.8) p < 0.05
Time interval to culture median (range)b )23 ()289 to 195) NA
Negative values indicate a positive test prior to culture; positive values indicate a positive test after positive culture.
NA, not applicable; NS, not signiﬁcant.
aA positive patient was deﬁned as yielding ‡1 positive sample.
bValues given in number of days; day 0, day of positive culture.
382 Clinical Microbiology and Infection, Volume 15 Number 4, April 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 380–386
diagnosis than in those collected from patients with <15 days
of neutropenia (Fig. 2; Fisher exact test, p <0.05). In all
patients, there was no clinical, radiological or microbiological
evidence of invasive candidiasis in the period preceding the
documentation of invasive candidiasis. Examples of the kinet-
ics of circulating mannan and anti-mannan antibodies in indi-
vidual patients are shown in Figs 3 and 4. In total, mannan
was detected in 13% of the samples of non-infected patients
with <15 days of neutropenia, which is signiﬁcantly less than
the rate in infected patients with <15 days of neutropenia,
where 36% of the samples were mannan-positive (p <0.05,
Fisher exact test). For non-infected and infected patients
with >15 days of neutropenia, 4% and 5%, respectively, of
the samples were mannan-positive; this difference was not
statistically different (p >0.05, Fisher exact test; Table 2).
The corresponding ORs for mannan-positive samples of
infected patients as compared to samples of control patients
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FIG. 1. Candida mannan in lg/L in individual plasma samples.
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FIG. 2. Anti-mannan antibody in Arithmetic Units per millilitre in
individual plasma samples.
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FIG. 3. Example of the kinetics of circulating anti-mannan antibodies and mannan in a 31-year-old male patient diagnosed with acute T-cell lym-
phoblastic leukaemia (ALL), who was treated according to the ALL-4 protocol. The patient underwent allogeneic haematopoietic stem cell trans-
plantation (AlloHSCT) in March 2004. A relapse of the ALL was diagnosed in September 2004, and the patient was treated with donor
lymphocyte infusion and methotrexate. The episodes of neutropenia and the corresponding treatment regimens are indicated. Candidaemia was
documented by positive blood culture in August 2004. Circulating anti-mannan antibodies (black line) were detected following the ﬁrst episode
of neutropenia. Circulating Candida-speciﬁc mannan (dotted black) was not detected in this patient, although, during two episodes of neutropenia
(episodes 1 and 3), the level increased but remained below the cut-off level.
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with <15 days and >15 days of neutropenia were 3.7
(95% CI 1.4–9.7) and 1.3 (95% CI 0.6–3.3), respectively.
Mean mannan levels in samples from patients with invasive
candidiasis and <15 days of neutropenia were signiﬁcantly
higher than those in the control group. For patients with
>15 days of neutropenia, no signiﬁcant differences in antigen
levels in the collected samples were observed (Table 3).
The proportions of anti-mannan antibody-positive samples
from infected and non-infected patients with <15 days of
neutropenia were 18% and 0%, respectively, and 52% and
11%, respectively, in samples from infected and control
patients with >15 days of neutropenia. These differences
were signiﬁcant (p <0.05, Fisher exact test; Table 2). The
corresponding OR for anti-mannan antibody-positive samples
of infected patients with <15 days of neutropenia could not
be calculated; for infected patients with >15 days of neutro-
penia, the OR was 8.9 (95% CI 5.6–14.3). In the per-patient
analysis, the proportion of antibody-positive patients with
>15 days of neutropenia was signiﬁcantly higher in the
infected group than in the control group (p <0.05, Fisher
exact test). The corresponding OR for a positive sample was
12.8 (95% CI 2.3–71.8). Comparisons between infected
patients and those of the control group with <15 days of
neutropenia who were antigen-positive or antibody-positive
revealed no signiﬁcant differences.
Discussion
The present study investigated the kinetics of circulating Can-
dida-speciﬁc mannan and anti-mannan antibodies in patients
undergoing myelo-ablative therapy with microbiologically
proven invasive candidiasis. Anti-mannan antibodies were
predominantly found in patients with >15 days of neutrope-
nia prior to microbiological documentation of invasive candi-
diasis. Differences, both in the per-sample and in the
per-patient analysis, were statistically signiﬁcant when com-
pared with the control group, which included patients who
were colonized or had superﬁcial infections with Candida. In
this study, these factors did not contribute to plasma reactiv-
ity. Mannan was predominantly detected in patients who
developed invasive candidiasis during their ﬁrst course of
chemotherapy, as reﬂected by the signiﬁcant differences
between samples from infected and non-infected patients
with <15 days of neutropenia. The predominance of anti-
mannan antibodies in patients who were neutropenic for
>15 days indicates that, during previous episodes of neutro-
penia, a clinically undetected Candida infection occurred,
thereby exposing the host to Candida cells or antigen. With
recovery of the neutrophils, an antibody response can be
detected. The kinetics as observed in individual patients are
TABLE 3. Mean antigen and antibody levels
Biological marker
Neutropenia
(days)
Mean
SigniﬁcanceaInfected Control
Mannan antigen (lg/L) <15 0.46 0.17 p < 0.05
>15 0.08 0.04 NS
Anti-mannan antibody
(AU/mL)
<15 5.06 0.05 p < 0.05
>15 11.84 1.53 p < 0.05
NS, not signiﬁcant.
aDifferences were compared using the Mann–Whitney U-test.
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FIG. 4. Example of the kinetics of circulating
anti-mannan antibodies and mannan in a
46-year-old male patient diagnosed with pre-
B-cell acute lymphoblastic leukaemia (ALL)
who was treated according to the ALL-4 pro-
tocol. The patient underwent an allogeneic
haematopoietic stem cell transplantation (Allo-
HSCT) in March 2001. The episodes of
neutropenia and the corresponding treatment
regimens are indicated. Circulating Candida-
speciﬁc mannan (dotted black) and anti-
mannan antibodies (black line) remained below
the cut-off level.
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consistent with this explanation (Fig. 3). In patients who
developed invasive candidiasis during their ﬁrst course of
chemotherapy, circulating mannan was the ﬁrst indicator of
infection, suggesting different kinetics of these biological
markers. In these patients, the immune system has not been
exposed to Candida or its antigens before, and consequently
circulating antibodies are not present.
No distinguishable pattern in the kinetics of antigen levels
as shown in Fig. 1 was observed in the control group, as
illustrated in an individual patient in Fig. 4. This was also true
for control patients who were categorized as positive in the
per-patient analysis, with the exception of the two individuals
described earlier.
It could be that these two patients had suffered from a
clinically undetected Candida infection. Thus, the mere pres-
ence of antigen or antibody in one or two samples does not
necessarily mean that the patient is, or has been, infected.
Although others have investigated the kinetics of Candida
antigen and antibodies in neutropenic patients [10,16,17], the
window of sampling in these studies was restricted to the
period shortly before and/or after the microbiological diag-
nosis was made. The present study, which investigated all
samples collected during consecutive treatment cycles, sug-
gests that circulating antibodies constitute a very early indica-
tor of invasive candidiasis in patients with multiple episodes
of neutropenia, an observation that is similar to that recently
reported for invasive aspergillosis. Antibodies directed
against recombinant Aspergillus cell wall antigens were found
in serum samples, obtained at admission, of c. 50% of the
patients who eventually developed invasive aspergillosis [18].
In both invasive aspergillosis and invasive candidiasis, the
pathogenesis of the infection is largely unknown; the present
observation and that of Sarfati et al. [18] indicate that sub-
clinical infections are likely to occur before clinically manifest
disease develops and microbiological conﬁrmation by culture
is achieved. Therefore, antibody detection might be a very
valuable biological marker that will help to identify those
patients who are at increased risk of developing these inva-
sive fungal diseases, and also to target intervention strategies.
However, the present study was limited by the relatively
small sample size, especially in the group with <15 days of
neutropenia, and therefore provides only a ‘proof of con-
cept’. Prospective studies are required to conﬁrm this obser-
vation before the beneﬁt of such strategies can be evaluated.
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